Completed PHASE4 INTERVENTIONAL 6-arm NCT06247488

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

Randomized, Double-blind, Active & Placebo-controlled, 6-way Crossover Study of Abuse Potential of Oral Gabapentin Enacarbil IR Capsules With and Without Oxycodone in Healthy, Nondependent, Recreational Opioid Users

Sponsor: Arbor Pharmaceuticals, Inc.

Conditions Abuse Potential

Interventions GE-IR 200 mg GE-IR 450 mg Oxycodone 20 mg Placebo

Updated 4 times since 2024 Last updated: Aug 9, 2024 Started: Jan 31, 2022 Primary completion: Apr 25, 2023 Completion: Apr 25, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Abuse Potential and is currently completed. Arbor Pharmaceuticals, Inc. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Aug 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2024 — Aug 2024 [monthly]

Completed PHASE4
Mar 2024 — Jul 2024 [monthly]

Completed PHASE4

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Arbor Pharmaceuticals, Inc.

Data source: Arbor Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States